GENEART Receives Major Contract from the Wellcome Trust Sanger Institute
News Nov 26, 2008
GENEART AG announces the closing of a major contract with the Wellcome Trust Sanger Institute, UK. GENEART will synthesize up to 600 tailor-made genes for the Wellcome Trust Sanger Institute's research program under this contract. The genes will be used to identify mechanisms involved in defined genetic and infectious disease. The terms of the agreement were not disclosed.
"We are very pleased that GENEART was selected for this project by the Wellcome Trust Sanger Institute during a tendering process. This emphasizes yet again our leading position in the market for gene synthesis. Worldwide largest capacities and our broad service portfolio allow us to meet specific customer requirements, even for large-scale contracts, in the shortest periods of time", stated Prof. Dr. Ralf Wagner, CEO of GENEART AG.
The program of research at the Wellcome Trust Sanger Institute uses large-scale technologies to understand the role of genes in health and disease and create lasting resources for biomedical research. By developing high throughput technologies to detect networks of extracellular protein interactions, the institute has identified new signaling pathways important for vertebrate development.
The Wellcome Trust Sanger Institute is now expanding the program of research to identify novel human extracellular receptor-ligand interactions involved in genetic diseases such as cardiovascular disease and also infectious diseases.
This program of research will involve screening for interactions within protein libraries that constitute the cell surface receptor repertoire of differentiated human blood cells, and also some pathogens. The protein libraries will also be used to determine the functional consequences of the identified interactions in cell-based assays.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE